Tenax Therapeutics Inc (TENX)
3.89
+0.14
(+3.73%)
USD |
NASDAQ |
Mar 18, 16:00
3.94
+0.05
(+1.29%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.160M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -91.76% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.1028 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.91% |
Profile
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction. |
URL | https://www.tenaxthera.com |
Investor Relations URL | http://investors.tenaxthera.com/ |
HQ State/Province | North Carolina |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction. |
URL | https://www.tenaxthera.com |
Investor Relations URL | http://investors.tenaxthera.com/ |
HQ State/Province | North Carolina |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |